Insmed Incorporated (NASDAQ:INSM) Receives Consensus Recommendation of “Buy” from Brokerages

Insmed Incorporated (NASDAQ:INSM) has earned an average rating of “Buy” from the sixteen ratings firms that are presently covering the stock, Marketbeat reports. Sixteen equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $94.00.

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. upped their target price on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Stifel Nicolaus lowered their target price on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Friday, February 21st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Insmed in a research note on Wednesday, March 19th. Finally, Guggenheim reissued a “buy” rating and set a $101.00 target price on shares of Insmed in a research note on Tuesday, February 25th.

Insiders Place Their Bets

In other news, CFO Sara Bonstein sold 1,066 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.72, for a total value of $67,925.52. Following the completion of the sale, the chief financial officer now directly owns 118,863 shares of the company’s stock, valued at $7,573,950.36. This represents a 0.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the transaction, the chief executive officer now directly owns 334,186 shares in the company, valued at $27,079,091.58. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 550,957 shares of company stock worth $42,992,528. 4.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Elequin Capital LP acquired a new stake in shares of Insmed during the 4th quarter valued at about $28,000. Steward Partners Investment Advisory LLC grew its position in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 163 shares in the last quarter. V Square Quantitative Management LLC increased its stake in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares during the last quarter. Spire Wealth Management bought a new position in shares of Insmed during the 4th quarter valued at $47,000. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 411 shares during the last quarter.

Insmed Price Performance

Shares of INSM opened at $77.99 on Friday. Insmed has a one year low of $21.92 and a one year high of $84.91. The stock’s fifty day moving average is $78.18 and its 200-day moving average is $73.99. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm has a market capitalization of $14.12 billion, a price-to-earnings ratio of -13.95 and a beta of 1.28.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Equities analysts anticipate that Insmed will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.